Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2014 Jul 18;14:398. doi: 10.1186/1471-2334-14-398

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2014 Franzetti et al.; licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

PMC Copyright notice

Trends in drug class usage and resistance at failure. Part A: Distribution of antiretroviral classes in use at time of genotyping when HIV-RNA > 1 Log copies/ml: trends of use are shown for nucleoside reverse-transcriptase inhibitors (NRTI, p < .0001*), non nucleoside reverse-transcriptase inhibitors (NNRTI, p < .0001*), protease inhibitors (PI, p < .0001*), Boosted PI (p < .0001*), antiretroviral regimens combining NRTI + NNRTI (p < .0001*), NRTI + PI (p < .0001*), NRTI + NNRTI + PI (p < .0001*). Part B: Prevalence of drug class resistance during the study period: trends of resistance are shown for NRTI (p < .0001*), NNRTI (p < .0001*), PI (p < .0001*), Boosted PI (p < .0001*), antiretroviral regimens combining NRTI + NNRTI (p < .0001*), NRTI + PI (p < .0001*), NRTI + NNRTI + PI (n.s.*). * Cochrane-Armitage test for trends.